The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
(PALSUR Trial)
Trial Summary
What is the purpose of this trial?
There is no consensus on the optimal treatment of patients with high-grade glioma, especially when patients have limited functioning performance at presentation (KPS ≤70). Therefore, there are varied practice patterns around pursuing biopsy, resection, or palliation (best supportive care). This study aims to characterize the impact of palliative care versus biopsy versus resection on survival and quality of life in these patients. Also, it will aim to determine if there is a subset of patients that benefit the most from resection or biopsy, for which outcome, and how they could be identified preoperatively. This study is an international, multicenter, prospective, 3-arm cohort study of observational nature. Consecutive HGG patients will be treated with palliative care, biopsy, or resection at a 1:3:3 ratio. Primary endpoints are: 1) overall survival, and 2) quality of life at 6 weeks, 3 months and 6 months after initial presentation based on the EQ-5D, EORTC QLQ C30 and EORTC BN 20 questionnaires. Total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year.
Research Team
Jasper Gerritsen, MD PhD
Principal Investigator
Erasmus Medical Center
Eligibility Criteria
Inclusion Criteria
Treatment Details
Find a Clinic Near You
Who Is Running the Clinical Trial?
Jasper Gerritsen
Lead Sponsor
University of California, San Francisco
Collaborator
Universitaire Ziekenhuizen KU Leuven
Collaborator
Haaglanden Medical Centre
Collaborator
University Hospital Heidelberg
Collaborator
Technical University of Munich
Collaborator
Massachusetts General Hospital
Collaborator
Insel Gruppe AG, University Hospital Bern
Collaborator